What’s going on with Moderna’s coronavirus vaccine?
Last week, we found out that Moderna’s closely watched coronavirus vaccine was going to be briefly delayed. This week, we found out the problem is internecine squabbling.
According to Reuters, Moderna’s scientists and executives have been less than cooperative with their partners at the National Institutes of Health, which is paying for the company’s 30,000-volunteer Phase 3 trial. Citing three people familiar with the process, Reuters reports that Moderna would be right on schedule if it didn’t “try to test every boundary,” as one person put it.
Moderna CEO Stéphane Bancel, speaking at the Fortune Brainstorm Health event yesterday, reaffirmed that the study would start by the end of this month and pointed to the inherent complexity of running large trials, likening the process to “landing a very big plane.”
This will all be a footnote in history if Moderna’s trial begins on time, and it may well be forgotten if the vaccine ends up working. But if the latest delay is the first in a series, it’ll be worth asking why similar problems didn’t plague the NIH’s other corporate collaborators.
According to Reuters, Moderna’s scientists and executives have been less than cooperative with their partners at the National Institutes of Health, which is paying for the company’s 30,000-volunteer Phase 3 trial. Citing three people familiar with the process, Reuters reports that Moderna would be right on schedule if it didn’t “try to test every boundary,” as one person put it.
Moderna CEO Stéphane Bancel, speaking at the Fortune Brainstorm Health event yesterday, reaffirmed that the study would start by the end of this month and pointed to the inherent complexity of running large trials, likening the process to “landing a very big plane.”
This will all be a footnote in history if Moderna’s trial begins on time, and it may well be forgotten if the vaccine ends up working. But if the latest delay is the first in a series, it’ll be worth asking why similar problems didn’t plague the NIH’s other corporate collaborators.
No hay comentarios:
Publicar un comentario